Skip to main content
OpenTrials
Completed

NCT Number: NCT01243307

A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

The primary objective of this study is to compare the effect of CT327 to placebo against experimental induced superficial, deep and hyperalgesic pain.

The secondary objectives are to elucidate the mechanisms of CT327 using experimental pain models.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Department of Gastroenterology Aalborg Hospital

Aalborg, 9000, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must be able to understand the contents of the study, comply with the study and willing to sign informed consent
  • Subjects must be free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory and other tests
  • All male subjects must take adequate contraceptive precautions during the course of the study and for 30 days after their participation in the study has ended

Exclusion criteria

  • Participation in other clinical studies within 3 months before screening
  • Scheduled for surgery, medical treatment or any hospital admission that would fall within the study
  • Use of strong painkillers
  • Use of any analgesic within 24 hours before start of study
  • Use of a regular course of prescribed medication and/or herbal medicine
  • The presence of lesions, significant scars, cuts, wounds, dermal abnormalities, tattoos or naevi in the test areas
  • A past history of contact dermatitis, psoriasis or keloid
  • Any clinically significant ECG abnormality at screening
  • A history of drug or other allergy that contraindicates his participation.
  • Regular or average consumption of more than 21 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 125 mL of wine or 20 mL of spirits).
  • Smokes more than five cigarettes (on average) per day, or had been a smoker of more than 5 cigarettes (on average) per day within the 3 months prior to screening.
  • A known history of drug or alcohol abuse.
  • As a result of the medical screening process, the PI or medical delegate considers the subject unfit for the study.
  • Use of any prescription medication within 2 weeks or 5 half-lives (whichever is longer) of dosing.
  • Use of non-prescription medication (e.g. aspirin, vitamins and herbal and dietary supplements) within 7 days prior to dosing, or 14 days if the medication contained grapefruit/ grapefruit juice or St John's Wort.

Treatment and study plan

CT327 (or placebo) followed by placebo (or CT327)

Drug

During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.

During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.

Primary outcomes

  1. An alteration in the peripheral sensitisation after treatment with CT327

    Time frame: 2 treatment/testing periods each lasting 4 days and separated by at least 10 days

Secondary outcomes

  1. The change in pain determined with the visual analogue scale (VAS) and the change in areas assessed with von Frey filaments and standardized brush.

    Time frame: 2 treatment/testing periods each lasting 4 days and separated by at least 10 days

Sponsors and collaborators

Lead sponsor

Creabilis SA

Industry

Collaborators

  • Aalborg University Hospital

Registry information

Official study title

A Phase I, Single-centre, Multiple-dose, Placebo-controlled Crossover Study to Investigate the Pharmacodynamic Effects of CT327 (0.1% Topical Cream) on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Nov 18, 2010
Registry last updated
Jun 8, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.